Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 88 clinical trials
Chemotherapy Combined With Immunotherapy in HER 2 Insertion or Amplification Advanced NSCLC

This study aims to explore the efficacy and safety of chemotherapy or chemotherapy plus PD-1 antibody in HER 2 insertion or amplification.

cancer chemotherapy
non-squamous non-small cell lung cancer
squamous non-small cell lung cancer
lung carcinoma
  • 0 views
  • 10 Mar, 2022
  • 1 location
The Establishment of a Survival Prediction Model for ER Positive / HER-2 Negative Advanced Breast Cancer

This project is a prospective, clinical cohort study initiated by researchers to study the high-risk factors affecting the overall survival of newly diagnosed ER + / HER2 - advanced breast cancer patients and to establish a prediction model of ER + / HER2 - advanced breast cancer patients affecting overall …

  • 0 views
  • 28 Jan, 2021
  • 2 locations
Bringing of PET-TDM FDG in the Determination of the Characteristics of Primary Mammary Tumors TrIple Negatives (FICTION)

"Triple Negative" breast cancers are a heterogeneous group characterized by the absence of hormone receptors to estrogen, progesterone and the absence of expression or amplification of the HER-2

progesterone
mastectomy
immunohistochemistry
erbb2
triple negative breast cancer
  • 0 views
  • 24 Feb, 2022
  • 1 location
Predictors of Response to Neoadjuvant Docetaxel-Carboplatin Chemotherapy for Patients With Stage II and III Triple Negative Breast Cancer

performed using FFEP tissue. Triple Negative Breast Cancer (TNBC) is defined by a lack of expression of ER, PgR and HER-2. DNA microarray profiling studies have led to the classification of invasive

carcinoma
HER2
anthracyclines
invasive breast cancer
breast carcinoma
  • 0 views
  • 04 Sep, 2021
  • 1 location
Radiomics of Mp-MRI Assessing NAC Outcome in Breast Cancer

This is a single-arm, multicentre study that aims to assess whether Radiomics combining multiparametric MRI and clinical data could be a good predictor of the responses to neoadjuvant chemotherapy in Breast Cancer.

invasive breast cancer
  • 1 views
  • 05 Mar, 2022
  • 1 location
Molecular Profiling After Neoadjuvant Chemotherapy for Triple-negative Breast Cancer

Neoadjuvant chemotherapy (NACT) can induce complete pathologic response (pCR) in approximately 35-55% of patient with triple-negative breast cancer (TNBC). These patients have excellent long term survivals. On the other hand patients with residual disease exhibit a high rate of local or metastatic. Although it has been successful in some regards, …

mastectomy
HER2
invasive breast cancer
breast cancer
erbb2
  • 0 views
  • 05 Mar, 2022
  • 1 location
IORT-Breast at MCNH

Intraoperative Breast Radiation Therapy (IORT-Breast) utilizing the Xoft Axxent Electronic Brachytherapy System (Xoft) has been recently introduced as a treatment option for women 50 years of age and older who have early stage, low risk Invasive Breast Cancer (IBC). Clinical trials have shown IORT to be non-inferior to whole breast …

  • 0 views
  • 26 Jan, 2021
  • 1 location
Intervention to Hepatic and Pulmonary Metastasis in Breast Cancer Patients

The number of intervention performed for metastatic breast cancer has dramatically increased over the past 2 decades. Hepatectomy and pulmonary resection for stage IV colorectal cancer is now considered the standard of care for resectable patients with isolated hepatic and/or pulmonary disease and acceptable performance status. However, the indications for …

stereotactic radiosurgery
radiofrequency ablation
liver metastasis
stage iv breast cancer
breast cancer
  • 223 views
  • 23 Jan, 2021
  • 1 location